Grace Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Grace Therapeutics stock has a target of 8.00, which predicts a 258.74% increase from the current stock price of 2.23.

Price Target: $8.00 (+258.74%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$8.00	$8.00	$8.00	$8.00
Change	+258.74%	+258.74%	+258.74%	+258.74%

Analyst Ratings

According to 1 stock analyst, the rating for Grace Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26
Strong Buy	1	1	1
Buy	0	0	0
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Stacy Ku TD Cowen	TD Cowen	Strong Buy Maintains $12 → $8	Strong Buy	Maintains	$12 → $8	+258.74%	Apr 24, 2026
Oren Livnat HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+438.12%	Feb 18, 2025

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

8.72M

EPS This Year

-0.86

from -0.79

EPS Next Year

-0.66

from -0.86

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	196.00K	-	-	-	-	-	8.72M
Revenue Growth	-	-	-	-	-	-	-
EPS	-7.96	-1.60	-5.71	-1.35	-0.79	-0.86	-0.66
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	10.5M
Avg	n/a	8.7M
Low	n/a	7.0M

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-0.62	-0.67
Avg	-0.86	-0.66
Low	-1.08	-0.64

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.